Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mega Genomics Limited ( (HK:6667) ) has issued an update.
Mega Genomics Limited has declared a final ordinary dividend of RMB 0.15 per share for the financial year ended 31 December 2025, reflecting its earnings performance and cash distribution policy for shareholders. The company has updated the payment timetable, with shareholder approval slated for 21 May 2026, an ex-dividend date of 26 May 2026, a record date of 29 May 2026, and a revised payment date of 9 July 2026.
The dividend will be paid in Hong Kong dollars with the precise amount and exchange rate to be announced, and Tricor Investor Services Limited will serve as share registrar for processing entitlements. The clarified schedule offers greater visibility for investors on expected cash returns and may support the stock’s appeal to income-focused shareholders as the company underlines its commitment to returning capital while maintaining regulatory transparency in Hong Kong.
More about Mega Genomics Limited
Mega Genomics Limited is a Hong Kong-listed company in the genomics and life sciences sector, providing genetic testing and related services to consumers and medical clients. The group focuses on the Chinese market and broader Asian region, leveraging diagnostic technologies to support healthcare, precision medicine, and health management applications.
Average Trading Volume: 7,078
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.57B
For a thorough assessment of 6667 stock, go to TipRanks’ Stock Analysis page.